China
Africa
Explore chapters and articles related to this topic
Recent Cannabinoid Delivery Systems
Published in Betty Wedman-St Louis, Cannabis as Medicine, 2019
Natascia Bruni, Carlo Della Pepa, Simonetta Oliaro-Bosso, Daniela Gastaldi, Franco Dosio, Enrica Pessione
Poly-ε-caprolactone (PCL) is another polymer that is widely used in drug delivery systems. This is a biocompatible, biodegradable, FDA-approved, semi-crystalline aliphatic polyester that degrades slowly. Hernán Pérez de la Ossa has developed a formulation in which CBD is loaded into PCL particles. Spherical microparticles, with a size range of 20–50 μm and high entrapment efficiency (around 100%), were obtained. CBD was slowly released over within ten days when dissolved in the polymeric matrix of the microspheres in an in vitro test [140].
Advances in stent technology
Published in John Edward Boland, David W. M. Muller, Interventional Cardiology and Cardiac Catheterisation, 2019
Smriti Saraf, Paul Bhamra-Ariza
The Ultimaster Stent is a thin-strut, CoCr, biodegradable-polymer, sirolimus-eluting coronary stent. It has an open cell two-link design with a stent strut thickness of 80 micron resulting in greater flexibility without compromising radial force. The polymer DL-lactide-co-caprolactone degrades over a period of 3–4 months and the drug is coated on the abluminal side preventing delamination. In the Century II multicentre trial, Ultimaster was compared to the Xience stent in 194 patients and no significant difference was noted in clinical outcomes at 1 year between the two arms.73
Molecular Targets and Optical Probes
Published in George C. Kagadis, Nancy L. Ford, Dimitrios N. Karnabatidis, George K. Loudos, Handbook of Small Animal Imaging, 2018
Eleni K. Efthimiadou, George Kordas
IONP stabilization by an organic layer can be performed either during nanoparticle synthesis (in situ coating) or following their synthesis (post-synthesis coating). The most commonly employed polymer-based stabilizers are either derived from natural materials such as dextran, starch, gelatin and chitosan, or from synthetic ones such as poly(ethylene glycol) (PEG), polyvinyl alcohol (PVA), poly(acrylic acid) (PAA), polymethylmethacrylate (PMMA), poly(lactide acid) (PLA), and alginate. Other polymers that have also been used are poly(ethyleneoxide)-b-poly(methacrylic acid), polyvinylpyrrolidone (PVP), polyethylenimine (PEI), ethylcellulose, poly(ε-caprolactone), sulfonated styrene-divinylbenzene, and arabinogalactan (Laurent et al. 2008; Wu et al. 2008).
Microneedle mediated transdermal delivery of β-sitosterol loaded nanostructured lipid nanoparticles for androgenic alopecia
Published in Drug Delivery, 2022
Kousalya Prabahar, Ubaidulla Udhumansha, Nehal Elsherbiny, Mona Qushawy
However, incorporating many lipophilic drugs into these hydrophilic polymeric MNs is very difficult. A particle-based MN system with antigen trapping in a polymeric nanoparticle was designed to release the antigen into the skin in a prolonged manner. The nanoparticles allow the release of entrapped drug in a controlled manner after releasing from the MN to the dermal layer, resulting in a long-acting effect at the site of action. Lipid-based particulate carriers, such as solid lipid nanoparticles (SLNs) and natural lipid nanoparticles (NLCs) have been introduced for the formulation of lipophilic drugs into water-soluble polymeric matrices because these drug-loaded nanoparticles can be dispersed homogeneously in an aqueous phase (Lee et al., 2014; Guo et al., 2018). A lot of studies were done to find effective solution for alopecia. Ushirobira et al. (2020) developed poly-(ɛ-caprolactone)-lipid-core nanocapsules (NC) containing duasteride for targeting the hair follicles and the results showed increase in the drug accumulation in hair follicle by 5 fold compared to the drug solution (Ushirobira et al., 2020). Oliveira et al. (2020) prepared a Poly-ε-caprolactone nanocapsules loading latanoprost for topical treatment of alopecia by nanoprecipitation of the polymer on the surface of drug oily nanodroplets and they found that Poly-ε-caprolactone nanocapsules delivered 30% more drug to these skin structures relative to the control solution of the drug (Oliveira et al., 2020).
Artemether-loaded polymeric lipid-core nanocapsules reduce cell viability and alter the antioxidant status of U-87 MG cells
Published in Pharmaceutical Development and Technology, 2022
Jader Pires, Suéllen Alves Costa, Karoline Paiva da Silva, Aline Gomes Batista da Conceição, Érica de Melo Reis, Adilson Paulo Sinhorin, Carmen Lucia Bassi Branco, Letícia Cruz, Stela Regina Ferrarini, Cláudia Marlise Balbinotti Andrade
The following listed materials, kits, and cells were used in the present study: Poly(ε-caprolactone, PCL 80 000® MW), polysorbate 80 (Tween 80®), sorbitan monostearate (Span 60®), Dulbecco’s Modified Eagle’s Medium–low glucose (DMEM, Sigma-D5523), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma-M5655), sulforhodamine B (SRB, Sigma-341738), dimethyl sulfoxide (DMSO, Sigma-D4540), ART (Sigma-1042780), streptomycin (Sigma-S9137), penicillin G (Sigma-P3032), sodium dodecyl sulfate (SDS, Sigma-S5136), paraformaldehyde (Sigma-P6148), fetal bovine serum (FBS, Gibco® 12657-029), Randox® commercial kits (TAS® NX2332, Ransod® SD125, Ransel® RS505, and GLUT RED® 2368), cell lines, ACBRI 371 (Cell Systems®), and U-87 MG (ATCC® HTB-14™). Other reagents and solvents used were of analytical grade.
Drug eluting implants in pharmaceutical development and clinical practice
Published in Expert Opinion on Drug Delivery, 2021
Ashley R. Johnson, Seth P. Forster, David White, Graciela Terife, Michael Lowinger, Ryan S. Teller, Stephanie E. Barrett
Poly(caprolactone) (PCL) is an attractive alternative [62] because its low melting point can prevent degradation of thermally labile drugs during melt extrusion. Poly(caprolactone) is a flexible polymer that degrades over years in preclinical models. It has been investigated since the 1970s and has wide precedence of use in medical devices. The degradation rate of PCL is slower than other biodegrable polymers like PLGA, which may have limited its use previously. Of note, the only poly(caprolactone) implant tested in clinical trials is Capronor®, a levonorgestrel containing reservoir implant with a poly(caprolactone) sheath. This drug eluting implant was developed by the Research Triangle Institute as a potential biodegradable alternative to existing non-degradable contraceptive implants; studies were discontinued after a successful phase II clinical trial [72]. This system was fabricated by solvent casting poly(caprolactone) films, heat sealing to form an open tube, and then filling the tube with an ethyl oleate- levonorgestrel suspension [72].